The new Democratic Congress is living up to expectations with plenty of bicameral pharma-bashing rhetoric, but has so far failed to implement price controls and ban DTC advertising. That doesn’t mean the industry should get comfy just yet.

Two Supreme Court rulings handed down in January stand to drastically alter the way pharma companies enter into licensing agreements and impact the future strength of drug patents, legal experts said.

The halt of Pfizer's torcetrapib program has potentially far-reaching implications for the broader industry and raises questions about safety of other drugs in its class, analysts said.

The FDA's Scott Gottlieb offered a conditional endorsement of the recommendations of the Institutes of Medicine report and vowed that the agency will communicate better by "approaching the social sciences in the same kind of way that we have approached the hard sciences."

Thought the question of consumer advertising was settled with PhRMA's DTC guidelines? Think again.

When Pfizer's board named a legal eagle and former McDonald's man to steer the sputtering behemoth through rocky shoals, they voted first for change.

Staffing concerns topped the list of the biggest challenges facing healthcare agencies in this year's MM&M's agency survey.